Navigation Links
Goat’s Milk One of the First Transgenic Food That Benefits Human

According to the researchers at the University of California, Davis it is found that a gene incorporated in to the goat, produces milk that has anti bacterial// enzyme found in human breast milk.

This milk altered the intestinal flora of the pigs and goats which were fed with the milk. Hence the researchers are anticipating that in the future they would be able to create a transgenic goat that produce milk which confers protection against diarrheal illnesses in children. According to the WHO statistics it was found that about 2 million worldwide die due to diarrheal illness. The study results were published in the international journal Transgenic Research. ‘This goat's milk represents one of the first transgenic food products that has the potential to really benefit human health,’ said Professor Jim Murray, who led the study along with Professor Gary Anderson and animal scientist Elizabeth Maga.

‘The results of the study indicate that the protective, antibacterial characteristics of lysozyme-rich human breast milk are also present in milk produced by transgenic goats that carry the gene for lysozyme.’ Lysozyme is a protein found in the tears, saliva and milk of all mammals. It is found at high levels in human breast milk, however goat's milk contains only 0.06 percent as much lysozyme as does human milk. Lysozyme inhibits the growth of bacteria by destroying the bacterial cell wall, causing the contents of the cell to leak out. Because lysozyme limits the growth of bacteria that cause intestinal infections and diarrhea, and encourages the growth of beneficial intestinal bacteria, lysozyme is considered to be one of the main components of human milk that contribute to the health and well-being of breast-fed infants.

For more than a decade, UC Davis researchers have been looking for ways to enrich the milk of cows and goats with some of the beneficial compounds like lysozyme that are found in human breast milk. About eight years ago, the
'"/>




Page: 1 2 3

Related medicine news :

1. First Vaccine Designed for Africa Cleared for Testing in Humans
2. Ajanta Launches Worlds First Once-A-Day Nimesulide Oral Formulation
3. First human clone is near
4. First Artificial Heart patient has Major setback
5. First head-to-head trials of once weekly Fosamax and Actonel therapies
6. WHO Declares Vietnam First Country to Control SARS
7. Russia Reports First SARS Case
8. Hope for First New Melanoma Treatment in Decades
9. First global SARS meet opens
10. Stanford Medical Center Implements The First Virtual Cardiac Ultrasound
11. Hyderabad To Have Asia’s First Catheter Making Uni
Post Your Comments:
(Date:5/17/2008)... as guide for avoiding exposure , , SAT...e earrings you bought from a hip young street arti...rs and skin. , A new report finds that many pai... Francisco stores and artists contain nickel, whic...d exposure can make treatment difficult. , The ...
(Date:5/16/2008)...ck; Merger Sets Up Healthy Back as the Nation...N, Va., May 16 /PRNewswire/ -- Healthy Back, the 1...ce back wellness created an,ergonomic revolution, ...JoAnne,s Bed & Back. Healthy Back,s 18 stores and ...lion. JoAnne,s 16 mid-Atlantic stores,claimed annu...
(Date:5/16/2008)...yroid hormone readings, study says , , F...tamin D and high levels of a hormone secreted by t...ression in older adults, according to a new report...e of Archives of General Psychiatry , supports pr...depression and other psychiatric illnesses are lin...
(Date:5/16/2008)...e of Oral and Overall Health, HARRISBURG, Pa., Ma...d,Concordia Dental is celebrating National Smile M...and the British Dental Health Foundation to,promot... Beginning May 18,this year,s event is launching ... the largest independent international dental heal...
Breaking Medicine News(10 mins):Health News:Cheaper Earrings More Likely to Contain Nickel 2Health News:Cheaper Earrings More Likely to Contain Nickel 3Health News:The Back Wars Come to a Close 2Health News:Low Vitamin D Tied to Depression in Older Adults 2Health News:United Concordia Dental Celebrates National Smile Month 2
...ed that women outlive men in Western countries, an... behavior on the part of men as the reason why.// ...than that. Another reason for the earlier demise o...to parasitic infections. In a report on the study,...
...ization or modernization, the Stress on human life...ey pay attention to the adoption of a more health...-opener for those people with fragile hearts.Most ... concern us.But this one moment of anger is suffic...
...tal new combination of drugs for Hepatitis -C Cure...tandard treatment for the potentially deadly,liver...ive doctors a more potent weapon against the virus...ge in cases of Hepatitis- C liver damage over the...
...there's a firm connection between viral infection ...research has shown that infection with human papil...l cancer. A group of almost 8,500 women with no h...h were followed for ten years. They had a cervical...
Other Medicine News:
(Date:5/16/2008)... Presentations at ASCO Annual Meeting Will Further...ns in Front-line Multiple Myeloma -, CAMBRIDGE, M...icals,The Takeda Oncology Company, today announce...scheduled to be featured at the 2008 American Soci...Chicago, Illinois, May 30 -,June 3, 2008. The data...
(Date:5/16/2008)...peakers include industry and customer thought lead...s, Inc., the recognized,leader and trusted resourc...hosted a constellation of prestigious academic med...artners at its annual user group meeting in San,Fr...rs to internally and,collaboratively manage thousa...
(Date:5/16/2008)...ts Include:, -- Results demonstrating that TYKERB... meaningful extension of progression-free survival...tack both the inside and,outside of the HER2 recep...Data demonstrating activity of TYKERB alone despit... of trastuzumab and chemotherapy, LONDON and PHIL...
(Date:5/16/2008)... N.J., May 16 /- Veridex, LLC announc...ry Corporation of America Holdings,(LabCorp), has ...for,prostate cancer. The new assay uses the biolog...cancer, detecting the methylation of the gene,GST-...rs primarily in,cancer. Veridex is developing the ...
Breaking Medicine Technology:New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 2New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 3New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 4New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 5New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 6New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 7New Data Support High Complete Remission Rates With VELCADE(R) (Bortezomib) for Injection Based Therapies in Patients With Newly Diagnosed Multiple Myeloma 8Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 2Top Academic Medical Centers, Research Institutions, and Partners Gather, Share Experiences and Success Stories at Velos eResearch Annual Meeting 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 2GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 3GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 4GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 5GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 6GSK Announces Results of First Phase III Trial Evaluating Tykerb(R) (Lapatinib) Plus Herceptin(R) (Trastuzumab) 7Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 1882 1Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 1882 2Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 1882 3Poniard Pharmaceuticals Announces Final Picoplatin Data from Phase 2 Small Cell Lung Cancer Trial Demonstrating Survival Benefit 1882 4Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver 1880 1Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver 1880 2Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver 1880 3Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver 1880 4Sleep Apnea Screening Cuts Surgical Complications 17520 1Sleep Apnea Screening Cuts Surgical Complications 17520 2The Quantum Group CEO to Deliver Keynote Address at EDC Life Science Conference 17518 1The Quantum Group CEO to Deliver Keynote Address at EDC Life Science Conference 17518 2The Quantum Group CEO to Deliver Keynote Address at EDC Life Science Conference 17518 3
...h Copaxone Plus Minocycline Showed Substantial,Red...,Relapsing-Remitting Multiple Sclerosis , Combinat...n,Lesions and Was Well Tolerated , KANSAS CITY, Mo...-blind study showed that a combination of Copaxone...l antibiotic,minocycline reduced T1 Gadolinium (Gd...
...o.--(BUSINESS WIRE)--May 4, 2007 - New data from a...ination of,COPAXONE(R) (glatiramer acetate injecti...uced T1 Gadolinium (Gd)-enhancing lesions,of the b...e,relapsing-remitting multiple sclerosis (RRMS), a...mpared to those receiving,COPAXONE(R) alone. Addit...
Other Medicine Technology:Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 6Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 7Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 8Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 9Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 10Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 11Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 12Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 2Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 3Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 4Treatment with Copaxone Plus Minocycline Showed Substantial,Reduction of Disease Activity in Patients with Active,Relapsing-Remitting Multiple Sclerosis 5
Inquire
Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the in vitro determination of Measles IgM antibodies in human serum. For in vitro diagnostic use. High complexity test.
...nzymelinked Immunosorbent Assays(ELISA) is intende... of IgG antibody to Measles Rubeola) virus in huma... the determination of immune status. Paired sera, ...te seroconversion or a significant rise in antibod...
The Diagnostic Automation, Inc. (DAI) Measles IgM Enzyme-Linked Immunosorbent Assay (ELISA) is intended for the in vitro determination of IgM antibody to Measles in human serum.
Medicine Products: